ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has received notification that Lanstead Capital LP has confirmed an increase in its holding in ImmuPharma. Lanstead now holds 6,985,893
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has announced today that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via
ImmuPharma’s Tim McCarthy discusses completion of their Lupuzor Phase III study in this exclusive interview with DirectorsTalk
Immupharma Plc (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the completion of the Lupuzor™ pivotal phase III study and an initiation of a follow up study. Tim explains the
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of
ImmuPharma issued an update on its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus. Key highlights included: 200 patients
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has this morning provided DirectorsTalk with an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor(TM),
ImmuPharma’s Tim McCarthy discusses their interim results & initiating Lupuzor’s regulatory submission in this exclusive interview with DirectorsTalk
ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company, wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L.P. in February 2016. As
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
